Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Z. Gabbasov, S. Kozlov, I. Melnikov, S. Byazrova, O. Saburova, L. Prokofieva, M. Caprnda, E. Curilla, L. Gaspar, L. Rodrigo, P. Kruzliak, V. Smirnov,

. 2018 ; 24 (8) : 1308-1314. [pub] 20180501

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000772

The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000772
003      
CZ-PrNML
005      
20190118104239.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1076029618771752 $2 doi
035    __
$a (PubMed)29716394
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gabbasov, Zufar $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
245    10
$a Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease / $c Z. Gabbasov, S. Kozlov, I. Melnikov, S. Byazrova, O. Saburova, L. Prokofieva, M. Caprnda, E. Curilla, L. Gaspar, L. Rodrigo, P. Kruzliak, V. Smirnov,
520    9_
$a The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a trombocyty $x metabolismus $x patologie $7 D001792
650    _2
$a nemoci koronárních tepen $x krev $x patologie $x chirurgie $7 D003324
650    _2
$a koronární restenóza $x krev $x patologie $7 D023903
650    _2
$a diabetes mellitus 2. typu $x krev $x patologie $x chirurgie $7 D003924
650    _2
$a diabetické angiopatie $x krev $x patologie $x chirurgie $7 D003925
650    12
$a stenty uvolňující léky $7 D054855
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD45 $x krev $7 D017493
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a počet trombocytů $7 D010976
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kozlov, Sergey $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
700    1_
$a Melnikov, Ivan $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation. 2 Institute of Biomedical Problems of Russian Academy of Sciences, Moscow, Russian Federation.
700    1_
$a Byazrova, Svetlana $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
700    1_
$a Saburova, Olga $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
700    1_
$a Prokofieva, Lyudmila $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
700    1_
$a Caprnda, Martin $u 3 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Curilla, Eduard $u 4 Department of Cardiology, East Slovak Institute of Cardiovascular Diseases, Kosice, Slovakia.
700    1_
$a Gaspar, Ludovit $u 3 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Rodrigo, Luis $u 5 Faculty of Medicne, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
700    1_
$a Kruzliak, Peter $u 6 Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic. 7 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Smirnov, Vladimir $u 1 Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
773    0_
$w MED00001108 $t Clinical and applied thrombosis/hemostasis official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis $x 1938-2723 $g Roč. 24, č. 8 (2018), s. 1308-1314
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29716394 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118104453 $b ABA008
999    __
$a ok $b bmc $g 1363918 $s 1038895
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 8 $d 1308-1314 $e 20180501 $i 1938-2723 $m Clinical and applied thrombosis/hemostasis $n Clin Appl Thromb Hemost $x MED00001108
LZP    __
$a Pubmed-20190107
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace